MONUROL (fosfomycin tromethamine) by Zambon is clinical pharmacology absorption: fosfomycin tromethamine is rapidly absorbed following oral administration and converted to the free acid, fosfomycin. Approved for urinary tract infection. First approved in 1996.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
MONUROL (fosfomycin tromethamine) is an oral antibiotic indicated for uncomplicated urinary tract infections and Pseudomonas infections. It works by inhibiting bacterial cell wall synthesis through a unique mechanism of action distinct from beta-lactams and fluoroquinolones. The drug is rapidly absorbed orally with peak serum concentrations achieved within 2-4 hours and achieves high urinary concentrations suitable for UTI treatment.
Product is in late-stage lifecycle with minimal market claims, indicating reduced team size and commercial investment focused on managed care maintenance rather than growth initiatives.
CLINICAL PHARMACOLOGY Absorption: Fosfomycin tromethamine is rapidly absorbed following oral administration and converted to the free acid, fosfomycin. Absolute oral bioavailability under fasting conditions is 37%. After a single 3 gram dose of fosfomycin tromethamine granules for oral solution,…
Worked on MONUROL at Zambon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults
Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on MONUROL offers limited growth trajectory but provides valuable experience in mature product management, generic transition strategy, and managed care negotiation in a crowded antibiotics market. This role is ideal for professionals seeking expertise in lifecycle management and cost-containment strategies rather than launch or expansion activities.